FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Derek Middlemiss

Research Profile

Chemicals & Drugs

Living Beings

Procedures

Radioligand Assay

Anatomy

Co-author Network

Publications

TOP 3
Tom D Heightman; Laramie M Gaster; Sarah L Pardoe; Jean-Pierre Pilleux; Michael S Hadley; Derek N Middlemiss; Gary W Price; Claire Roberts; Claire M Scott; Jeannette M Watson; Laurie J Gordon; Vicky Holland; Jenifer Powles; Graham J Riley; Tania O Stean; Brenda K Trail; Neil Upton; Nigel E Austin; Andrew Ayrton; Tanya Coleman; Leanne Cutler
8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
Zoë A Hughes; Kathryn R Starr; Christopher J Langmead; Matthew Hill; Gerd D Bartoszyk; James Hagan; Derek N Middlemiss; Lee A Dawson
Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
Peter J Atkinson; Steven M Bromidge; Mark S Duxon; Laramie M Gaster; Michael S Hadley; Beverley Hammond; Christopher N Johnson; Derek N Middlemiss; Stephanie E North; Gary W Price; Harshad K Rami; Graham J Riley; Claire M Scott; Tracey E Shaw; Kathryn R Starr; Geoffrey Stemp; Kevin M Thewlis; David R Thomas; Mervyn Thompson; Antonio K K Vong; Jeannette M Watson
3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Derek Middlemiss (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2005: Tom D Heightman; Laramie M Gaster; Sarah L Pardoe; Jean-Pierre Pilleux; Michael S Hadley; Derek N Middlemiss; Gary W Price; Claire Roberts; Claire M Scott; Jeannette M Watson; Laurie J Gordon; Vicky Holland; Jenifer Powles; Graham J Riley; Tania O Stean; Brenda K Trail; Neil Upton; Nigel E Austin; Andrew Ayrton; Tanya Coleman; Leanne Cutler
8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
Bioorganic & medicinal chemistry letters 2005;15(19):4370-4.
2005: Zoë A Hughes; Kathryn R Starr; Christopher J Langmead; Matthew Hill; Gerd D Bartoszyk; James Hagan; Derek N Middlemiss; Lee A Dawson
Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
European journal of pharmacology 2005;510(1-2):49-57.
2005: Peter J Atkinson; Steven M Bromidge; Mark S Duxon; Laramie M Gaster; Michael S Hadley; Beverley Hammond; Christopher N Johnson; Derek N Middlemiss; Stephanie E North; Gary W Price; Harshad K Rami; Graham J Riley; Claire M Scott; Tracey E Shaw; Kathryn R Starr; Geoffrey Stemp; Kevin M Thewlis; David R Thomas; Mervyn Thompson; Antonio K K Vong; Jeannette M Watson
3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activity.
Bioorganic & medicinal chemistry letters 2005;15(3):737-41.
2003: Gregor Macdonald; Clive L Branch; Michael S Hadley; Christopher N Johnson; David J Nash; Alexander B Smith; Geoffrey Stemp; Kevin M Thewlis; Antonio K K Vong; Nigel E Austin; Phillip Jeffrey; Kim Y Winborn; Izzy Boyfield; James Hagan; Derek N Middlemiss; Charlie Reavill; Graham J Riley; Jeannette M Watson; Martyn Wood; Steve G Parker; Charles R Ashby Jr
Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.
Journal of medicinal chemistry 2003;46(23):4952-64.
2003: David R Thomas; Sergio Melotto; Mario Massagrande; Andrew D Gribble; Phillip Jeffrey; Alexander J Stevens; Nigel J Deeks; Peter J Eddershaw; Susan H Fenwick; Graham Riley; Tania O Stean; Claire M Scott; Matthew J Hill; Derek N Middlemiss; James Hagan; Gary W Price; Ian T Forbes
SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats.
British journal of pharmacology 2003;139(4):705-14.
2003: V L Bush; Derek N Middlemiss; Charles A Marsden; Kevin C F Fone
Implantation of a slow release corticosterone pellet induces long-term alterations in serotonergic neurochemistry in the rat brain.
Journal of neuroendocrinology 2003;15(6):607-13.
2003: John W Clitherow; Frank D King; Derek N Middlemiss; Paul A Wyman
The discovery and development of 5-HT-terminal autoreceptor antagonists.
Progress in medicinal chemistry 2003;41():129-65.
2002: Thomas Blackburn; Yoshio Minabe; Derek N Middlemiss; Yukihiko Shirayama; Kenji Hashimoto; Charles R Ashby
Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study.
Synapse (New York, N.Y.) 2002;46(3):129-39.
2002: Stanislav R Vorel; Charles R Ashby; Mousumi Paul; Xinhe Liu; Robert Hayes; James Hagan; Derek N Middlemiss; Geoffrey Stemp; Eliot L Gardner
Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002;22(21):9595-603.
2002: Derek N Middlemiss; Gary W Price; Jeannette M Watson
Serotonergic targets in depression.
Current opinion in pharmacology 2002;2(1):18-22.
2002: David R Thomas; Peter J Atkinson; P G Hastie; J C Roberts; Derek N Middlemiss; Gary W Price
[3H]-SB-269970 radiolabels 5-HT7 receptors in rodent, pig and primate brain tissues.
Neuropharmacology 2002;42(1):74-81.
2001: C Roberts; Gary W Price; Derek N Middlemiss
Ligands for the investigation of 5-HT autoreceptor function.
Brain research bulletin 2001;56(5):463-9.
2001: Martyn D Wood; Charlie Reavill; Brenda K Trail; A Wilson; Tania O Stean; Guy A Kennett; S Lightowler; Thomas Blackburn; D Thomas; TL Gager; Graham Riley; Vicky Holland; Steven M Bromidge; Ian T Forbes; Derek N Middlemiss
SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety.
Neuropharmacology 2001;41(2):186-99.
2001: Vera Ralevic; David A Kendall; Jeffrey C Jerman; Derek N Middlemiss; Darren Smart
Cannabinoid activation of recombinant and endogenous vanilloid receptors.
European journal of pharmacology 2001;424(3):211-9.
2001: Jeannette Watson; Claire Roberts; Claire Scott; I Kendall; LJ Collin; N C Day; Mark H Harries; Ellen M Soffin; Ceri H Davies; Andrew D Randall; T Heightman; Laramie M Gaster; Paul A Wyman; C Parker; Gary W Price; Derek N Middlemiss
SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue.
British journal of pharmacology 2001;133(6):797-806.
2001: Andrew D Medhurst; Frank Lezoualc'h; Rodolphe Fischmeister; Derek N Middlemiss; GJ Sanger
Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by TaqMan real time RT-PCR.
Brain research. Molecular brain research 2001;90(2):125-34.
2001: Vera Ralevic; David A Kendall; Jeffrey C Jerman; John B Davis; Derek N Middlemiss; Darren Smart
Low pH modulation of recombinant vanilloid receptors and perivascular capsaicin-sensitive sensory neurotransmission.
Autonomic neuroscience : basic & clinical 2001;88(1-2):36-44.
2001: Claire Roberts; L Allen; Christopher J Langmead; James Hagan; Derek N Middlemiss; Gary W Price
The effect of SB-269970, a 5-HT(7) receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies.
British journal of pharmacology 2001;132(7):1574-80.
2001: Jeffrey C Jerman; Stephen J Brough; TL Gager; M Wood; Martin Coldwell; Darren Smart; Derek N Middlemiss
Pharmacological characterisation of human 5-HT2 receptor subtypes.
European journal of pharmacology 2001;414(1):23-30.
2001: Claire Roberts; J Watson; Gary W Price; Derek N Middlemiss
SB-236057-A: a selective 5-HT1B receptor inverse agonist.
CNS drug reviews 2001;7(4):433-44.
2000: M K Farmer; Melanie J Robbins; Andrew D Medhurst; D A Campbell; K Ellington; Malcolm Duckworth; A M Brown; Derek N Middlemiss; Gary W Price; Menelas Pangalos
Cloning and characterization of human NTT5 and v7-3: two orphan transporters of the Na+/Cl- -dependent neurotransmitter transporter gene family.
Genomics 2000;70(2):241-52.
2000: Charles R Ashby; Y Minabe; Geoffrey Stemp; James Hagan; Derek N Middlemiss
Acute and chronic administration of the selective D(3) receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study.
The Journal of pharmacology and experimental therapeutics 2000;294(3):1166-74.
2000: Charlie Reavill; SG Taylor; Martyn D Wood; Tracey E Ashmeade; Nigel E Austin; KY Avenell; Izzy Boyfield; Clive L Branch; Jackie Cilia; Martin Coldwell; Michael S Hadley; A Jackie Hunter; Phillip Jeffrey; FR Jewitt; Christopher N Johnson; Declan N C Jones; Andrew D Medhurst; Derek N Middlemiss; David J Nash; Graham J Riley; Carol Routledge; Geoffrey Stemp; Kevin M Thewlis; Brenda K Trail; Antonio K K Vong; James Hagan
Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
The Journal of pharmacology and experimental therapeutics 2000;294(3):1154-65.
2000: Steven M Bromidge; S Davies; DM Duckworth; Ian T Forbes; GE Jones; J Jones; Frank D King; Thomas Blackburn; Vicky Holland; Guy A Kennett; S Lightowler; Derek N Middlemiss; Graham J Riley; Brenda K Trail; Martyn D Wood
1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.
Bioorganic & medicinal chemistry letters 2000;10(16):1867-70.
2000: Steven M Bromidge; S Dabbs; S Davies; DM Duckworth; Ian T Forbes; GE Jones; J Jones; Frank D King; DV Saunders; Thomas Blackburn; Vicky Holland; Guy A Kennett; S Lightowler; Derek N Middlemiss; Graham J Riley; Brenda K Trail; Martyn D Wood
1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.
Bioorganic & medicinal chemistry letters 2000;10(16):1863-6.
2000: Claire Roberts; Paula D Hatcher; James Hagan; Nigel E Austin; Phillip Jeffrey; Paul A Wyman; Laramie M Gaster; Carol Routledge; Derek N Middlemiss
The effect of SB-236057-A, a selective 5-HT1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely-moving guinea-pig.
Naunyn-Schmiedeberg's archives of pharmacology 2000;362(2):177-83.
2000: Carol Routledge; Steven M Bromidge; S F Moss; Gary W Price; Warren D Hirst; H Newman; Graham Riley; TL Gager; Tania O Stean; Neil Upton; S E Clarke; AM Brown; Derek N Middlemiss
Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist.
British journal of pharmacology 2000;130(7):1606-12.
2000: Warren D Hirst; Jayne A L Minton; Steven M Bromidge; S F Moss; A J Latter; Graham Riley; Carol Routledge; Derek N Middlemiss; Gary W Price
Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue.
British journal of pharmacology 2000;130(7):1597-605.
2000: Melanie J Robbins; David Michalovich; jeffrey hill; Andy Robert Calver; Andrew D Medhurst; IS Gloger; M Sims; Derek N Middlemiss; Menelas Pangalos
Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C).
Genomics 2000;67(1):8-18.
2000: James Hagan; Gary W Price; Phillip Jeffrey; Nigel J Deeks; Tania O Stean; DC Piper; Martin I Smith; Neil Upton; Andrew D Medhurst; Derek N Middlemiss; Graham J Riley; Peter J Lovell; Steven M Bromidge; David R Thomas
Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist.
British journal of pharmacology 2000;130(3):539-48.
2000: Geoffrey Stemp; Tracey E Ashmeade; Clive L Branch; Michael S Hadley; A Jackie Hunter; Christopher N Johnson; David J Nash; Kevin M Thewlis; Antonio K K Vong; Nigel E Austin; Phillip Jeffrey; KY Avenell; Izzy Boyfield; James Hagan; Derek N Middlemiss; Charlie Reavill; Graham J Riley; Carol Routledge; Martyn Wood
Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat.
Journal of medicinal chemistry 2000;43(9):1878-85.
2000: David R Thomas; Peter J Atkinson; M Ho; Steven M Bromidge; Peter J Lovell; A J Villani; James Hagan; Derek N Middlemiss; Gary W Price
[(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors.
British journal of pharmacology 2000;130(2):409-17.
2000: Steven M Bromidge; S Dabbs; DT Davies; S Davies; DM Duckworth; Ian T Forbes; Laramie M Gaster; P Ham; GE Jones; Frank D King; KR Mulholland; DV Saunders; Paul A Wyman; Frank E Blaney; Stephen E Clarke; Thomas Blackburn; Vicky Holland; Guy A Kennett; S Lightowler; Derek N Middlemiss; Brenda K Trail; Graham J Riley; Martyn D Wood
Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.
Journal of medicinal chemistry 2000;43(6):1123-34.
2000: Peter J Lovell; Steven M Bromidge; S Dabbs; DM Duckworth; Ian T Forbes; AJ Jennings; Frank D King; Derek N Middlemiss; S K Rahman; DV Saunders; L L Collin; James Hagan; Graham J Riley; David R Thomas
A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
Journal of medicinal chemistry 2000;43(3):342-5.
2000: Andy Robert Calver; Andrew D Medhurst; Melanie J Robbins; Kelly J Charles; ML Evans; David C Harrison; M Stammers; S A Hughes; Guillaume J Hervieu; Andrés Couve; Stephen J Moss; Derek N Middlemiss; Menelas Pangalos
The expression of GABA(B1) and GABA(B2) receptor subunits in the cNS differs from that in peripheral tissues.
Neuroscience 2000;100(1):155-70.
1999: David R Thomas; Derek N Middlemiss; SG Taylor; P Nelson; AM Brown
5-CT stimulation of adenylyl cyclase activity in guinea-pig hippocampus: evidence for involvement of 5-HT7 and 5-HT1A receptors.
British journal of pharmacology 1999;128(1):158-64.
1999: Darren Smart; Jeffrey C Jerman; Stephen J Brough; S L Rushton; Paul R Murdock; FR Jewitt; Nabil A Elshourbagy; CE Ellis; Derek N Middlemiss; F Brown
Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR.
British journal of pharmacology 1999;128(1):1-3.
1999: C Roberts; D F Boyd; Derek N Middlemiss; Carol Routledge
Enhancement of 5-HT1B and 5-HT1D receptor antagonist effects on extracellular 5-HT levels in the guinea-pig brain following concurrent 5-HT1A or 5-HT re-uptake site blockade.
Neuropharmacology 1999;38(9):1409-19.
1999: Martin Coldwell; Izzy Boyfield; T Brown; James Hagan; Derek N Middlemiss
Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
British journal of pharmacology 1999;127(7):1696-702.
1999: Martin Coldwell; Izzy Boyfield; AM Brown; Geoffrey Stemp; Derek N Middlemiss
Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
British journal of pharmacology 1999;127(5):1135-44.
1999: Derek N Middlemiss; Manfred Göthert; Eberhard Schlicker; Claire M Scott; Julie V Selkirk; Jeannette Watson; Laramie M Gaster; Paul A Wyman; Graham Riley; Gary W Price
SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor.
European journal of pharmacology 1999;375(1-3):359-65.
1999: Declan N C Jones; Rudie Kortekaas; Paula D Hatcher; Derek N Middlemiss; A White; James Hagan
Influence of peptide CRF receptor antagonists upon the behavioural effects of human/rat CRF.
European journal of pharmacology 1999;373(2-3):141-5.
1999: Martyn D Wood; KL Murkitt; M Ho; J M Watson; F Brown; A Jackie Hunter; Derek N Middlemiss
Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry.
British journal of pharmacology 1999;126(7):1620-4.
1999: J M Watson; A Jackie Hunter; AM Brown; Derek N Middlemiss
In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes.
European journal of pharmacology 1999;370(1):69-77.
1999: Steven M Bromidge; AM Brown; Stephen E Clarke; K Dodgson; TL Gager; H L Grassam; Phillip Jeffrey; GF Joiner; Frank D King; Derek N Middlemiss; Stephen F Moss; Helen Newman; Graham Riley; Carol Routledge; Paul A Wyman
5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.
Journal of medicinal chemistry 1999;42(2):202-5.
1998: Laramie M Gaster; P Ham; GF Joiner; Frank D King; KR Mulholland; Paul A Wyman; James Hagan; Gary W Price; Claire Roberts; Carol Routledge; Julie V Selkirk; P D Slade; Derek N Middlemiss
The selective 5-HT1B receptor inverse agonist SB-224289, potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.
Annals of the New York Academy of Sciences 1998;861():270-1.
1998: J Watson; Stephen J Brough; Martin Coldwell; TL Gager; M Ho; A Jackie Hunter; Jeffrey C Jerman; Derek N Middlemiss; Graham J Riley; AM Brown
Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
British journal of pharmacology 1998;125(7):1413-20.
1998: Neil Upton; Tania O Stean; Derek N Middlemiss; Thomas Blackburn; Guy A Kennett
Studies on the role of 5-HT2C and 5-HT2B receptors in regulating generalised seizure threshold in rodents.
European journal of pharmacology 1998;359(1):33-40.
1998: Julie V Selkirk; Claire Scott; M Ho; M J Burton; Jeannette Watson; Laramie M Gaster; LJ Collin; BJ Jones; Derek N Middlemiss; Gary W Price
SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity.
British journal of pharmacology 1998;125(1):202-8.
1998: David R Thomas; S A Gittins; L L Collin; Derek N Middlemiss; Graham Riley; J Hagan; IS Gloger; CE Ellis; Ian T Forbes; AM Brown
Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719.
British journal of pharmacology 1998;124(6):1300-6.
1998: Declan N C Jones; Rudie Kortekaas; P D Slade; Derek N Middlemiss; James Hagan
The behavioural effects of corticotropin-releasing factor-related peptides in rats.
Psychopharmacology 1998;138(2):124-32.
1998: C Roberts; A Belenguer; Derek N Middlemiss; Carol Routledge
Differential effects of 5-HT1B/1D receptor antagonists in dorsal and median raphe innervated brain regions.
European journal of pharmacology 1998;346(2-3):175-80.
1998: Laramie M Gaster; Frank E Blaney; S Davies; DM Duckworth; P Ham; S Jenkins; AJ Jennings; GF Joiner; Frank D King; KR Mulholland; Paul A Wyman; James Hagan; Jonathan P Hatcher; BJ Jones; Derek N Middlemiss; Gary W Price; Graham Riley; Claire Roberts; Carol Routledge; Julie V Selkirk; P D Slade
The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.
Journal of medicinal chemistry 1998;41(8):1218-35.
1998: Ian T Forbes; S Dabbs; DM Duckworth; AJ Jennings; Frank D King; Peter J Lovell; AM Brown; LJ Collin; James Hagan; Derek N Middlemiss; Graham J Riley; David R Thomas; Neil Upton
(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist.
Journal of medicinal chemistry 1998;41(5):655-7.
1997: Eberhard Schlicker; Klaus Fink; Gerhard J Molderings; Gary W Price; Malcolm Duckworth; Laramie M Gaster; Derek N Middlemiss; Josef Zentner; James A Likungu; Manfred Göthert
Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors.
Naunyn-Schmiedeberg's archives of pharmacology 1997;356(3):321-7.
1997: Gary W Price; M J Burton; LJ Collin; Malcolm Duckworth; Laramie M Gaster; Manfred Göthert; BJ Jones; Claire Roberts; Jeannette M Watson; Derek N Middlemiss
SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors.
Naunyn-Schmiedeberg's archives of pharmacology 1997;356(3):312-20.
1997: Hugh J Herdon; Jeffrey C Jerman; Tania O Stean; Derek N Middlemiss; WN Chan; Antonio K K Vong; JM Evans; Mervyn Thompson; Neil Upton
Characterization of the binding of [3H]-SB-204269, a radiolabelled form of the new anticonvulsant SB-204269, to a novel binding site in rat brain membranes.
British journal of pharmacology 1997;121(8):1687-91.
1997: James Hagan; P D Slade; Laramie M Gaster; Phillip Jeffrey; Jonathan P Hatcher; Derek N Middlemiss
Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig.
European journal of pharmacology 1997;331(2-3):169-74.
1997: Guy A Kennett; Martyn D Wood; F Bright; Brenda K Trail; Graham Riley; Vicky Holland; KY Avenell; Tania O Stean; Neil Upton; Steven M Bromidge; Ian T Forbes; AM Brown; Derek N Middlemiss; Thomas Blackburn
SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist.
Neuropharmacology 1997;36(4-5):609-20.
1997: Claire Roberts; Gary W Price; Laramie M Gaster; BJ Jones; Derek N Middlemiss; Carol Routledge
Importance of h5-HT1B receptor selectivity for 5-HT terminal autoreceptor activity: an in vivo microdialysis study in the freely-moving guinea-pig.
Neuropharmacology 1997;36(4-5):549-57.
1996: Hugh J Herdon; Jeffrey C Jerman; Tania O Stean; W Chan; Derek N Middlemiss; Neil Upton
The novel anticonvulsant SB 204269 binds to a stereospecific site in the mouse brain.
European journal of pharmacology 1996;314(3):R7-8.
1996: J M Watson; M J Burton; Gary W Price; BJ Jones; Derek N Middlemiss
GR127935 acts as a partial agonist at recombinant human 5-HT1D alpha and 5-HT1D beta receptors.
European journal of pharmacology 1996;314(3):365-72.
1996: Izzy Boyfield; T H Brown; Martin Coldwell; D G Cooper; Michael S Hadley; James Hagan; M A Healy; A Johns; R J King; Derek N Middlemiss; David J Nash; Graham J Riley; E E Scott; Stephen A Smith; Geoffrey Stemp
Design and synthesis of 2-naphthoate esters as selective dopamine D4 antagonists.
Journal of medicinal chemistry 1996;39(10):1946-8.
1996: Gary W Price; Claire Roberts; J Watson; M Burton; K Mulholland; Derek N Middlemiss; BJ Jones
Species differences in 5-HT autoreceptors.
Behavioural brain research 1996;73(1-2):79-82.
1995: V J Storey; Derek N Middlemiss; C Reavill
Effect of haloperidol and (-)-sulpiride on dopamine agonist-induced hypoactivity.
Neuropharmacology 1995;34(4):449-55.